Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

5α-Dihydroethisterone

From Wikipedia, the free encyclopedia
(Redirected fromDihydroethisterone)
Chemical compound
Pharmaceutical compound
5α-Dihydroethisterone
Clinical data
Other namesHE-3562; 5α-Dihydro-17α-Ethynyltestosterone; 17α-Ethynyl-DHT; 17α-Ethynyl-5α-androstan-17β-ol-3-one; 5α,17α-Pregn-20-yn-17β-ol-3-one; Ethynylandrostanolone
Drug classProgestin;Progestogen;Androgen;Anabolic steroid
Identifiers
  • (5S,8R,9S,10S,13S,14S,17R)-17-ethynyl-17-hydroxy-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-one
CAS Number
PubChemCID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC21H30O2
Molar mass314.469 g·mol−1
3D model (JSmol)
  • C[C@]12CCC(=O)C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C#C)O)C
  • InChI=1S/C21H30O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,14,16-18,23H,5-13H2,2-3H3/t14-,16+,17-,18-,19-,20-,21-/m0/s1
  • Key:PVHMKHVQVIUQIP-JJFNZWTKSA-N

5α-Dihydroethisterone (5α-DHET; developmental code nameHE-3562) is anactive metabolite of the formerly clinically used but now-discontinuedprogestinethisterone and the experimental and never-marketedhormonal antineoplastic agentethynylandrostanediol (HE-3235).[1][2] Its formation from its parent drugs iscatalyzed by5α-reductase intissues that express theenzyme in high amounts like theliver,skin,hair follicles, andprostate gland.[1][2][3] 5α-DHET has significantaffinity forsteroid hormone receptors and may contribute importantly to the activities of its parent drugs.[1][2]

Pharmacology

[edit]

Pharmacodynamics

[edit]

Theaffinity of 5α-DHET for theandrogen receptor (AR) is relatively high, in the range of 38 to 100% of that ofdihydrotestosterone (DHT).[1][2][4] A study found that, similarly tonorethisterone and its 5α-reduced metabolite5α-dihydronorethisterone, 5α-DHET showed increased affinity for the AR but decreasedandrogenicpotency relative to ethisterone (Ki = 16.1 nM for 5α-DHET and 101.1 nM for ethisterone, a 6-fold difference in affinity).[1] The decreased androgenic activity of 5α-DHET in spite of increased affinity for the AR relative to ethisterone suggests that it has comparatively reducedefficacy as anagonist of the receptor, analogously toselective androgen receptor modulators (ARpartial agonists) andantiandrogens (ARantagonists).[1] 5α-DHET has relatively low affinity for theprogesterone receptor, only about 12% of that of theprogestogenprogesterone.[2] This is significantly less than that of ethisterone, which has been found to bind to the receptor with an affinity of 35% of that of progesterone.[5][6][7] Conversely, it has relatively high affinity for theglucocorticoid receptor, about 120% of that of thecorticosteroiddexamethasone.[2] In regards to theestrogen receptors, 5α-DHET has weak affinity for theERα of about 3.5% of that ofestradiol, and does not bind to theERβ (Ki > 10 μM).[2]

In addition to steroid hormone receptors, 5α-DHET has very high affinity forsex hormone-binding globulin (Kd = 0.18 nM), anandrogen andestrogenbinding and transport protein that has the effect of intermittently inactivatingsteroid hormones (but also prolonging theirhalf-life in the body).[8][9][10] Its affinity for this protein is among the highest of any known compound and has been found to be roughly equal to that of DHT andmesterolone (1α-methyl-DHT).[8][9][10] This property may contribute to the androgenic activity of 5α-DHET's parent drug ethisterone by displacingendogenous androgens liketestosterone and DHT from SHBG.[11]

Pharmacokinetics

[edit]

Metabolism studies of ethynylandrostanediol revealed that 5α-DHET can be metabolized via C7β and C16αhydroxylation.[2]

Chemistry

[edit]
See also:List of progestogens andList of androgens/anabolic steroids

5α-DHET, also known as 5α-dihydro-17α-ethynyltestosterone (17α-ethynyl-DHT) as well as 17α-ethynyl-5α-androstan-17β-ol-3-one or 5α,17α-pregn-20-yn-17β-ol-3-one, is asyntheticandrostanesteroid and aderivative oftestosterone.[1][2] It is specifically the combined derivative of5α-dihydrotestosterone (DHT) andethisterone (17α-ethynyltestosterone).[1][2] The steroid is also closely related toethynylandrostanediol (17α-ethynyl-5α-androstane-3α,17β-diol).[2]

Analogues

[edit]

Some closely related synthetic 5α-reduced steroid metabolites include5α-dihydronandrolone,5α-dihydronormethandrone,5α-dihydronorethandrolone,5α-dihydronorethisterone, and5α-dihydrolevonorgestrel, as well as19-norandrosterone and19-noretiocholanolone.

Derivatives

[edit]

Thesteroidal antiandrogenzanoterone (WIN-49596), which was investigated in the 1990s for the treatment ofbenign prostatic hyperplasia but was never marketed, was derived from 5α-DHET.[12][13] In terms ofchemical structure, it is 5α-DHET with apyrazolering-containingmoiety fused at the C2 and C3 positions.[14]

Synthesis

[edit]

Apartial synthesis of 5α-DHET fromandrostenedione has been published.[15]

References

[edit]
  1. ^abcdefghLemus AE, Enríquez J, García GA, Grillasca I, Pérez-Palacios G (January 1997). "5alpha-reduction of norethisterone enhances its binding affinity for androgen receptors but diminishes its androgenic potency".J. Steroid Biochem. Mol. Biol.60 (1–2):121–9.doi:10.1016/S0960-0760(96)00172-0.PMID 9182866.S2CID 33771349.
  2. ^abcdefghijkAhlem C, Kennedy M, Page T, Bell D, Delorme E, Villegas S, Reading C, White S, Stickney D, Frincke J (February 2012). "17α-alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism".Invest New Drugs.30 (1):59–78.doi:10.1007/s10637-010-9517-0.PMID 20814732.S2CID 24785562.
  3. ^Dunaway G (1 April 2009)."Androgens and Antiandrogens". In Watts S, Faingold C, Dunaway G, Crespo L (eds.).Brody's Human Pharmacology - E-Book. Elsevier Health Sciences. pp. 468–.ISBN 978-0-323-07575-6.
  4. ^Cunningham GR, Lobl TJ, Cockrell C, Shao TC, Tindall DJ (May 1983). "Characterization of steroid binding specificity of the androgen receptor in human foreskin fibroblasts".Steroids.41 (5):617–26.doi:10.1016/0039-128X(83)90027-2.PMID 6658893.S2CID 9932822.
  5. ^Ojasoo T, Raynaud JP, Doé JC (January 1994). "Affiliations among steroid receptors as revealed by multivariate analysis of steroid binding data".J. Steroid Biochem. Mol. Biol.48 (1):31–46.doi:10.1016/0960-0760(94)90248-8.PMID 8136304.S2CID 21336380.
  6. ^Ojasoo T, Raynaud JP (November 1978)."Unique steroid congeners for receptor studies".Cancer Res.38 (11 Pt 2):4186–98.PMID 359134.
  7. ^Delettré J, Mornon JP, Lepicard G, Ojasoo T, Raynaud JP (January 1980). "Steroid flexibility and receptor specificity".J. Steroid Biochem.13 (1):45–59.doi:10.1016/0022-4731(80)90112-0.PMID 7382482.
  8. ^abCunningham GR, Tindall DJ, Lobl TJ, Campbell JA, Means AR (September 1981). "Steroid structural requirements for high affinity binding to human sex steroid binding protein (SBP)".Steroids.38 (3):243–62.doi:10.1016/0039-128X(81)90061-1.PMID 7197818.S2CID 2702353.
  9. ^abCherkasov A, Ban F, Santos-Filho O, Thorsteinson N, Fallahi M, Hammond GL (April 2008)."An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin".J. Med. Chem.51 (7):2047–56.doi:10.1021/jm7011485.PMID 18330978.
  10. ^abNikolic K, Filipic S, Agbaba D (December 2012). "Multi-target QSAR and docking study of steroids binding to corticosteroid-binding globulin and sex hormone-binding globulin".Curr Comput-Aided Drug Des.8 (4):296–308.doi:10.2174/157340912803519642.PMID 22242800.
  11. ^Llewellyn W (2011).Anabolics. Molecular Nutrition Llc. pp. 641–.ISBN 978-0-9828280-1-4.
  12. ^Mallamo JP, Juniewicz PE (8 September 1989)."New Horizons in the Treatment of Proliferative Prostatic Disease". In Johns WF (ed.).Annual Reports in Medicinal Chemistry. Vol. 24. Academic Press. pp. 200–.doi:10.1016/S0065-7743(08)60543-6.ISBN 978-0-08-058368-6.
  13. ^Lednicer D, Mitscher LA (5 November 1998).The Organic Chemistry of Drug Synthesis. John Wiley & Sons. p. 65.ISBN 978-0-471-24510-0.
  14. ^William Andrew Publishing (22 October 2013).Pharmaceutical Manufacturing Encyclopedia (3rd ed.). Elsevier. pp. 3517–.ISBN 978-0-8155-1856-3.
  15. ^Scaros MG, Yonan PK, Paul K, Schulz J, Park JC (2001). "Novel preparation of 5α-dihydroethisterone from androst-4-ene-3,17-dione.".Chemical Industries. Vol. 82 (Catalysis of Organic Reactions). Dekker. pp. 307–313.ISSN 0737-8025.
ARTooltip Androgen receptor
Agonists
SARMsTooltip Selective androgen receptor modulator
Antagonists
GPRC6A
Agonists
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
GRTooltip Glucocorticoid receptor
Agonists
Mixed
(SEGRMsTooltip Selective glucocorticoid receptor agonists)
Antagonists
Others
PRTooltip Progesterone receptor
Agonists
Mixed
(SPRMsTooltip Selective progesterone receptor modulators)
Antagonists
mPRTooltip Membrane progesterone receptor
(PAQRTooltip Progestin and adipoQ receptor)
Agonists
Antagonists
Retrieved from "https://en.wikipedia.org/w/index.php?title=5α-Dihydroethisterone&oldid=1303035367"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp